Events

Rappel de Shiley Neonatal, Paediatric and Long Paediatric Tracheostomy Tube, Cuffless and with TaperGuard Cuff

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Covidien Pty Ltd.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    RC-2015-RN-00412-1
  • Classe de risque de l'événement
    Class I
  • Date de mise en oeuvre de l'événement
    2015-05-13
  • Pays de l'événement
    Australia
  • Source de l'événement
    DHTGA
  • URL de la source de l'événement
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2015-RN-00412-1
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    Covidien is conducting this recall following reports from customers where patients who recently switched from the current shiley neonatal and pediatric products to these affected products as listed above, experienced discomfort immediately after the switch in a limited number of situations. in some cases, breathing difficulties, corresponding to a negative effect on oxygen levels, were also observed immediately after the switch. in all reported cases, patients were administered immediate medical attention. serious injuries, events that required medical intervention, have occurred or could occur due to the failure mode associated with this recall. there have been 12 reports of serious injuries. no deaths have been reported.
  • Action
    Covidien is requesting hospitals to discontinue use and quarantine all affected devices. Covidien will organise for the recovery of the affected devices. If one of the recalled Shiley tracheostomy tubes is currently in use in a patient, and the patient is not experiencing any discomfort, breathing difficulties or any other issues related to the tube, Covidien recommends that the patient’s physician evaluate the continued use.

Device

Shiley Neonatal, Paediatric and Long Paediatric Tracheostomy Tube, Cuffless and with TaperGuard Cuff
  • Modèle / numéro de série
    Shiley Neonatal, Paediatric and Long Paediatric Tracheostomy Tube, Cuffless and with TaperGuard CuffNeonatal -Tracheostomy Tube Cuffless 2.5NEF, 3.0NEF, 3.5NEF, 4.0NEF & 4.5NEF-Tracheostomy Tube with TaperGuard Cuff2.5NCF, 3.0NCF, 3.5NCFPediatric -Tracheostomy Tube Cuffless 2.5PEF, 3.0PEF, 3.5PEF, 4.0PEF, 4.5PEF, 5.0PEF, 5.5PEF-Tracheostomy Tube Long Cuffless5.0PELF, 5.5PELF, 6.0PELF, 6.5PELFAll lot numbers beginning with 12, 13 and 14 & 15A0152JZX & 15A0154JZX
  • Classification du dispositif
    Anesthesiology Devices
  • Manufacturer
    Covidien Pty Ltd

Manufacturer

Covidien Pty Ltd
  • Société-mère du fabricant (2017)
    Medtronic plc
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    DHTGA